Enter your search terms:


Kieth Kendall

Keith J. Kendall,
Chief Executive Officer

Keith Kendall assumed the role of Chief Executive Officer at Aquestive in 2014 after serving as Co-president and Chief Operating Officer for the Company since 2011.  Mr. Kendall also served as Executive Vice President and Chief Financial Officer of Aquestive since July 2006.  From February 1999 to June 2006, he was the Vice President and Managing Director of the Americas for Hewlett Packard Financial Services.  Mr. Kendall held a number of positions with AT&T Capital Corporation including President of AT&T Credit Corporation and NCR Credit Corporation from 1985 to 1998.

Dan Barber

Daniel Barber,
Chief Strategy and Development Officer

Daniel Barber joined Aquestive in July 2007.  Prior to joining Aquestive, Mr. Barber held various positions with Quest Diagnostics in their corporate planning and international divisions.  Over the last ten years Mr. Barber has been instrumental in the growth of Aquestive Therapeutics.  In 2010, Mr. Barber had executive oversight of the company’s launch activities for Aquestive’s first two FDA approved products.  In 2013, Mr. Barber helped lead the company’s effort to develop an internal pipeline of proprietary assets.  Since that time he has had executive responsibility for Aquestive’s pipeline and partnership activities.  Mr. Barber received his BA degree from State University of New York at Geneseo and an MBA from Seton Hall University.

Peter Boyd

Peter Boyd,
Senior Vice President Value Delivery

Peter Boyd joined the Aquestive team in August of 2013 to oversee project delivery.  Prior to joining the Company, Mr. Boyd served as Senior Director of Operations for the Americas and APJ Regions, at Hewlett-Packard Company.  Throughout his 15-year career at Hewlett-Packard Company, Mr. Boyd held a variety of positons in business process improvement and in operations.  Mr. Boyd earned a BA in History from Wittenberg University and a MBA in Finance from Seton Hall University.  Mr. Boyd also earned a Master’s of Science in Management and Urban Policy Analysis from the New School University in New York, NY.

Lori J. Braender,
General Counsel


Lori J. Braender has served as our Senior Vice President, General Counsel since September 2018. Prior to joining our team, Ms. Braender was a partner at the law firm Day Pitney LLP where she served in various roles for over 35 years, including, prior to her departure, as the Chair of the firm’s Life Sciences Practice Group. Ms. Braender holds a BS from Rider University and a JD from Seton Hall University School of Law.

Ken Marshall,
Chief Commercial Officer

Ken Marshall joined Aquestive in 2017. Prior to that Mr. Marshall served as US President and Global Chief Marketing Officer for Aerocrine Inc. In that role he developed the global marketing strategy and led all aspects of the US business. Between 2008 and 2011, Mr. Marshall served as Vice President of Sales and Marketing for Ikaria, a drug/device company focused in critical care. Mr. Marshall also spent 17 years with GlaxoSmithKline and held several senior positions including Vice President of Marketing for the Neurology, Urology, Lifecycle and HIV business units. Mr. Marshall received his BS/BA in Marketing and Economics from Western Carolina University and M.B.A from Houston Baptist University.

John Maxwell

John T. Maxwell,
Chief Financial Officer

John Maxwell joined Aquestive in January 2017.  Prior to joining Aquestive, Mr. Maxwell held senior financial roles at WIL Research, InfoNXX, PanAmSat, ADP and General Signal.  He started his career at Ernst & Young, serving in the Dallas, New York and Stamford offices.  Since 2000, Mr. Maxwell has helped lead the successful strategic sale transactions by the private equity sponsors of WIL Research in early 2016 to Charles River Labs and PanAmSat in mid-2006 to Intelsat.  Mr. Maxwell also helped lead the NYSE IPO of PanAmSat in 2005 and multiple public and private debt transactions for WIL Research, InfoNXX and PanAmSat.  Mr. Maxwell is a Certified Public Accountant, and holds a BBA in Accounting from Texas Tech University and a MBA in Finance/International Business from New York University Stern School of Business.

Mark Schobel

Mark Schobel,
Chief Innovation & Technology Officer

Mark Schobel was appointed as Chief Innovation & Technology Officer of Aquestive in 2014 after serving as the Company’s Chief Executive Officer, Co-President and a member of its Board of Directors since November 2005.  From March 2001 to November 2005, he was the Global Head of New Technology and Product Innovation for the Consumer Health Business Unit at Novartis where he pioneered thin film delivery of systemic drugs.  Prior to Novartis, Mr. Schobel held various general management positions with Reed & Carnrick Pharmaceuticals, Warner-Lambert, and Pharmaceutical Formulations Inc.

Gary H. Slatko, M.D. - Senior Vice President, Chief Medical Officer

Gary H. Slatko, M.D.,
Senior Vice President, Chief Medical Officer


Dr. Slatko’s experience includes six years in drug safety regulatory work at the U.S. Food and Drug Administration as a director in the Office of Medication Error Prevention and Risk Management. He also spent over a decade of time as the CMO of a biopharmaceutical consulting firm, ParagonRx, a Syneos Health (formerly InVentiv Health) company. Previously, he held various drug safety, clinical program, new product planning, medical affairs, and executive leadership roles over a 15-year pharmaceutical industry career at Squibb, DuPont Merck, AstraZeneca, and GlaxoSmithKline. Dr. Slatko received a B.A. from Emory University, a M.D. from the University of Miami School of Medicine, and a M.B.A. from West Chester University. He is Board certified in Internal Medicine.

Theresa Wood

Theresa Wood,
Senior Vice President Human Resources

Theresa Wood has led the Human Resources function since October 2006.  Prior to joining Aquestive, Ms. Wood was the Director, Human Resources for Hewlett Packard Financial Services’ Americas division from 1999 to 2006.  From 1995 to 1998, Ms. Wood provided consulting services to several companies in the Financial Services, Healthcare and Consumer Goods market.  Prior to that, Ms. Wood spent seven years with Sea-Land Service Corp.

Doug Bratton

Douglas Bratton,
Board of Directors

Douglas Bratton has served as Aquestive’s Chairman of the Board since 2004.  He is the Founder, President, and CIO of Crestline Investors. Founded in 1997, Crestline is an institutional alternative investment management firm with approximately $9.2 billion of assets under management.  Crestline specializes in credit and opportunistic investments, including financing restructuring solutions for mature private equity funds.  In addition, the firm manages a multi-PM equity market-neutral hedge fund, and provides Beta and Hedging Solutions for Institutional clients.  Headquartered in Fort Worth, Texas, the company maintains offices in New York City, Chicago, London, Toronto, and Tokyo.  Mr. Bratton has been an investment professional specializing in alternative asset strategies since 1983 and has managed assets on behalf of the Bass family of Fort Worth, Texas, since 1988.  Mr. Bratton received a BS from North Carolina State University in 1981 and a Masters of Business Administration with Honors from Duke University in 1984.  Mr. Bratton serves on the Boards of Bounty Minerals Corporation and the Board of Visitors of Duke University’s Fuqua School of Business.

Greg Brown

Dr. Gregory Brown,
Board of Directors

Gregory Brown joined Aquestive’s Board of Directors in March 2007. Dr. Brown is a co-founder and Vice Chairman at HealthCare Royalty Partners (HCR) and Chairman of the firm’s Strategic Advisory Board. Educated as a transplantation immunologist and trained as a thoracic and vascular surgeon, Dr. Brown practiced thoracic and vascular surgery in a community setting where he also founded and led an HMO. He brings particular expertise in the scientific, technical, clinical and medical evaluation of products as well as in healthcare systems and payor / reimbursement dynamics. He has been involved in sourcing, diligencing and closing more than $1 billion of royalty financings. Before co-founding HCR, Dr. Brown was a partner at Paul Capital Partners, where he co-managed that firm’s royalty investments as a member of the royalty management committee. Prior to beginning his principal investment career in 2003, Dr. Brown was co-head of investment banking and head of healthcare at Adams, Harkness & Hill (now Canaccord Genuity) and a ranked biotechnology research analyst at Vector Securities International. Dr. Brown holds a B.A. from Yale, an M.D. from SUNY Upstate Medical Center and an M.B.A. from Harvard Business School. He currently serves on the boards of Caladrius Biosciences, Faron Pharmaceuticals and Aquestive.

John Cochran

John Cochran,
Board of Directors

John Cochran has served on Aquestive’s Board of Directors since 2004.  He has been a partner of Bratton Capital Management L.P. since October 1998, and is responsible for its private equity investments.  Mr. Cochran is also responsible for the operations of Crestline Management, a credit-oriented alternative asset management platform.  Prior to joining Bratton Capital Management L.P., he spent 10 years with KPMG focused primarily on audit and merger and acquisition due diligence.  Mr. Cochran received his B.A. in Accounting from Texas Christian University and is also a licensed certified public accountant.

Sandy Costa

Santo Costa,
Board of Directors

Santo Costa joined Aquestive’s Board of Directors in 2015.  His professional experience includes over 30 years in executive and senior operating management positions within the pharmaceutical, health care, and life sciences industries.  Currently, Mr. Costa sits on the board of Cytokinetics Inc. and is chairman of Metabon Inc.  He has also served as a board member to numerous other public and private companies and charitable organizations.  Mr. Costa is Of Counsel at the law firm Smith, Anderson, Blount, Dorsett, Mitchell and Jernigan in Raleigh, N.C.  In addition to his legal practice, Mr. Costa’s experience includes President, Chief Operating Officer, and Vice Chairman of Quintiles Transnational Corp. where during his tenure he had responsibility for all operating divisions and worldwide business development.  He is also a nationally recognized speaker on leadership, as well as legal and policy issues affecting the pharmaceutical industry.  Mr. Costa earned a B.S. in Pharmacy and his J.D. from St. John’s University.

Nancy Lurker,
Board of Directors

Nancy Lurker joined Aquestive’s Board of Directors in April 2018. Ms. Lurker currently serves as President and Chief Executive Officer of EyePoint Pharmaceuticals, Inc., a specialty biopharmaceutical company committed to developing and commercializing innovative ophthalmic products. Before joining EyePoint Pharmaceuticals, she was Senior Vice President and Chief Marketing Officer of Novartis U.S. Pharmaceuticals Corporation and held senior positions at leading pharmaceutical companies including Pharmacia Corporation (now a part of Pfizer, Inc.) and Bristol-Myers Squibb Company.  Ms. Lurker serves as a member of the board of directors of EyePoint Pharmaceuticals and the Cancer Treatment Centers of America, and is a member of the Novo A/S Advisory Group. She received a B.S. in Biology from Seattle Pacific University and an M.B.A. from the University of Evansville.

Jim Scibetta

James S. Scibetta,
Board of Directors

James Scibetta joined Aquestive’s Board of Directors in 2017.  He is currently CEO of Maverick Therapeutics, a development stage immune-oncology company.  Prior to Maverick, Mr. Scibetta was President of Pacira Pharmaceuticals (Nasdaq: PCRX) where he oversaw commercial and medical support activities, and directed commercial manufacturing, tech transfer, and R&D.  Mr. Scibetta served as Pacira’s Chief Financial Officer from 2008 through May 2016 where he led its 2011 IPO and subsequent debt and equity financings.  Prior to that, he was an executive with Bioenvision Inc. (Nasdaq: BIVN), a commercial stage oncology company acquired by Genzyme, and Merrimack Pharmaceuticals, an oncology-focused systems biology company.  Earlier in his career he spent over a decade in investment banking where he was responsible for sourcing and executing transactions for a broad base of public and private healthcare and life sciences companies.  He serves as a Board director and chairman of the audit committee of Matinas BioPharma (NYSE: MTNB).  Mr. Scibetta received his B.S. in Physics from Wake Forest University and his MBA from the University of Michigan.

Latest comments

Sorry, the comment form is closed at this time.